Omthera Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Omthera Pharmaceuticals is betting that its so-called "free" fatty acid form of omega-3 will prove superior to other companies' ethyl esther versions at reducing blood triglyceride levels. An ethyl ester is a free fatty acid with an ethanol bond on it; that bond is broken in the intestines by pancreatic lipase, an enzyme specialized in breaking down fat. In Omthera's version of omega-3 fatty acid, that bond is broken already. The company thinks the difference will allow the free form to more effectively reduce TGL levels.
You may also be interested in...
Diabetes Drug Development: Seeing Light In The Dark Ages?
Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.
Omthera Looks To Take Lead In Omega-3 Space, Armed With Data Showing Advantages Over Lovaza
Privately held New Jersey firm expects data from pivotal Phase III trial of Epanova during first half of 2012, with NDA to follow shortly.
Omthera Looks To Take Lead In Omega-3 Space, Armed With Data Showing Advantages Over Lovaza
Privately held New Jersey firm expects data from pivotal Phase III trial of Epanova during first half of 2012, with NDA to follow shortly.